Are there opportunities for Biovail that will come out of health care reforms in the U.S.?
There are opportunities being created by the mergers and acquisitions that are going on in big pharma. As these companies merge they have to go through their own restructurings. That means they tend to get rid of products which are not core to them. They also usually reduce head count, so we can get some very good people that we would never have a chance at, under other circumstances. It is a little hard to tell what [the health care reform] is going to look like. One thing is clear. You will have a larger proportion of the population having health insurance, so you will have a larger market. There may be some pricing pressure associated with that, but our assumption is that the increase in market size is going to more than offset any pricing pressure. Are the regulatory problems you faced in Canada and the U.S. behind you? We’ve settled all the regulatory issues. We still do have some legacy costs because we are indemnifying some of our former officers, who have not finished their pro
